Why the study?
Does desmopressin (DDAVP) reduce bleeding time in patients treated with heparin for acute venous thromboembolism?
Does desmopressin (DDAVP) reduce bleeding time in patients treated with heparin for acute venous thromboembolism?
Desmopressin (DDAVP) partially reverses the prolongation of bleeding time induced by heparin, suggesting it may be useful for managing heparin-associated hemorrhagic complications.
Answers are grounded in this paper and cite their sources.
May support DDAVP for heparin-related bleeding complications; extends RCT evidence to acute VTE patients.
The effect on the bleeding time of heparin, followed by an infusion with desmopressin (DDAVP) 0.3 micrograms/kg or placebo in a randomized, double-blind set-up, was investigated in 20 patients treated for acute venous thromboembolism. The bleeding time was on the average prolonged by 90% (95% confidence interval 46%-134%) after at least 1 day of treatment with heparin. At that point DDAVP shortened the bleeding time by 23% with a confidence interval of -35% to -11% whereas the effect of placebo was -2% with a confidence interval of -23% to +20%. There was also a shortening of the APTT after DDAVP but not after placebo. It is concluded that DDAVP induces a partial reversal of the effect of heparin on the bleeding time, and that DDAVP should be tried in case of hemorrhagic problems.
No takes yet. Share an insight, caveat, or question.
Schulman et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: